Exelixis
EXEL
#1660
Rank
NZ$17.35 B
Marketcap
$60.76
Share price
1.26%
Change (1 day)
70.33%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): NZ$0.96 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.08 Billion. In 2023 the company made an earning of NZ$0.43 Billion, an increase over its 2022 earnings that were of NZ$0.39 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$0.96 B124.72%
2023 NZ$0.43 B9.89%
2022 NZ$0.39 B-20.33%
2021 NZ$0.49 B124.82%
2020 NZ$0.21 B-67.14%
2019 NZ$0.66 B-11.94%
2018 NZ$0.75 B185.09%
2017 NZ$0.26 B-325.82%
2016 -NZ$0.12 Billion-58.12%
2015 -NZ$0.29 Billion-37.61%
2014 -NZ$0.46 Billion9.75%
2013 -NZ$0.42 Billion65.96%
2012 -NZ$0.25 Billion-291.63%
2011 NZ$0.12 B-195.59%
2010 -NZ$0.14 Billion-42.17%
2009 -NZ$0.24 Billion-18.98%
2008 -NZ$0.29 Billion-6.99%
2007 -NZ$0.31 Billion46.3%
2006 -NZ$0.22 Billion33.25%
2005 -NZ$0.16 Billion-30.92%
2004 -NZ$0.24 Billion44.29%
2003 -NZ$0.16 Billion12.86%
2002 -NZ$0.15 Billion22.79%
2001 -NZ$0.12 Billion60.14%
2000 -NZ$71.85 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
NZ$6.99 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$12.41 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$27.63 B 2,648.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$11.54 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$7.84 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$30.83 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$2.04 Billion-302.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$78.13 Million-107.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$48.68 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA